Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

Stopped early · Phase 2

Conditions studied: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma

In brief

This is a phase II study designed to investigate the combination of bortezomib with the mitoxantrone reinduction regimen used in the ALL R3 trial. The study will enroll patients with high risk ALL relapse including early bone marrow relapse and second or greater relapse of any kind. Patients with relapsed LL will also be eligible. Bone marrow evaluation will be performed after blood counts recover to assess the rate of CR (\<5% bone marrow blasts) and MRD status in children following this regimen. Further treatment with or without HSCT will be at the discretion of the primary physician.

Key facts

Study ID
NCT02535806
Run by
Children's Mercy Hospital Kansas City
People needed
2
Starts
2015-07-01
Expected to finish
2017-05-25
Last updated by the study team
2019-08-13

Who can join

Age: 1 and older, up to 39. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.